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Background: The prognostic value of the three constituents of undifferentiated-type gastric adenocarcinoma
remains unclear. The present study assessed the clinicopathological characteristics and prognosis of
undifferentiated-type mucinous adenocarcinoma (uMAC) and signet ring cell carcinoma (SRC) compared with those
of poorly differentiated adenocarcinoma (PDAC).
Methods: In total, 1,376 patients with undifferentiated-type gastric adenocarcinoma were included, consisting of
1,002 patients diagnosed with PDAC, 54 with uMAC and 320 with SRC. Clinicopathological factors and survival rates
were compared among the three histological types.
Results: Significant differences in the distribution of pathological stages were observed among the groups. Patients
with SRC had a significantly better survival rate than those with PDAC or uMAC, in both the all patients including
non-curative resected patients and curative-resected groups. In addition, there was significant difference in survival
between the PDAC and uMAC groups. Multivariate analysis suggested that age, gender, tumor depth, lymph
node metastasis and curability significantly affected survival. Histological type was not an independent prognostic
factor. There was no significant difference in the pattern of recurrence among the three groups.
Conclusions: The uMAC and SRC had worse and favorable prognosis compared with PDCA, respectively. However,
there were no differences in survival by pathological stage, thus histological type was not an independent predictor
of prognosis.
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According to the World Health Organization (WHO)
classification, the four predominant histological types of
gastric adenocarcinoma are tubular adenocarcinoma, pap-
illary adenocarcinoma, mucinous adenocarcinoma (MAC)
and signet ring cell carcinoma (SRC) [1]. Unlike tubular
adenocarcinoma, which is graded as well-, moderately- or
poorly-differentiated according to the degree of glandular
formation, papillary adenocarcinoma is usually classified
as well-differentiated, and SRC as poorly-differentiated.
The Japanese classification system categorizes gastric
adenocarcinomas into two groups: differentiated and
undifferentiated. The differentiated group consists of* Correspondence: painkiller9@catholic.ac.kr
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reproduction in any medium, provided the orwell-differentiated, moderately-differentiated and papillary
adenocarcinoma. The undifferentiated group consists of
poorly differentiated adenocarcinoma (PDAC) and SRC.
Interestingly, MAC can be regarded as either a differen-
tiated or undifferentiated type depending on the predom-
inant components [2]. In the same context, Nakamura
categorized all gastric cancer as either differentiated or
undifferentiated [3,4].
Undifferentiated-type gastric adenocarcinomas in gen-
eral have a worse prognosis. The innate characteristics
and prognosis of MAC and SRC have been studied
[5-18]. However, the results of those studies are still
debated. Although MAC definitely has a dismal prog-
nosis, several studies have reported that this is due to
its typically advanced stage at diagnosis, rather than its
cellular nature [17-20]. In addition, the clinicopathological
features of SRC remain unclear. Some studies reported
that early-stage gastric SRC was associated with a better. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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SRC histology was not an independent prognostic factor
[6-9]. Others insisted that SRC had a prognosis similar to
non-SRC [13,14], or that SRC was an independent pre-
dictor of a poor prognosis [15]. However, most studies
have compared one type, such as MAC or SRC, with all
other types of gastric cancer. Our hypothesis was that a
comparison limited to only undifferentiated types would
provide a more practical analysis. Moreover, an appro-
priate standard of comparison is required to clarify the
oncologic significance of these cell types. Therefore, in
this study, we set PDAC as the comparison object in
order to determine the characteristics of particular
histologies, such as MAC and SRC.Methods
Definition
In accordance with the WHO [1] and the Japanese Gas-
tric Cancer Association (JGCA) [2], we defined PDAC
as tubular adenocarcinoma composed of highly irregular
glands that are recognized with difficulty, or single cells
that remain isolated or are arranged in small or large
clusters. MAC and SRC were defined as tumors in which
more than 50% of the tumor area contained extracellular
mucin pools and tumors consisting of isolated or small
groups of malignant cells containing intracytoplasmic
mucin, respectively.
Patients
Between 1989 and 2005, a total of 2,709 patients diag-
nosed with gastric cancer underwent surgery at Seoul St.
Mary’s Hospital. All of the surgical procedures were per-
formed by three experienced gastric surgeons of our sin-
gle institution with a definitive treatment guideline for
gastric cancer. An eligibility criterion was patients who
underwent gastrectomy accompanied by lymph node dis-
section with a primary gastric adenocarcinoma. Patients
with synchronous malignancies or remnant gastric can-
cer and those who were diagnosed as differentiated-type
adenocarcinoma (papillary adenocarcinoma, well and
moderately tubular adenocarcinma, and differentiated-
type MAC) were excluded from the present study.
Finally, 1,002 patients histologically diagnosed as PDAC,
54 diagnosed as undifferentiated-type MAC (uMAC),
and 320 diagnosed as SRC were enrolled in the study.
Clinicopathological parameters, including gender and age
of patients; number, size and location of tumors; depth of
invasion; lymph node metastasis status; lymphovascular
and perineural invasion; and operative details, were col-
lected retrospectively from the Gastric Cancer Patients
Registry of Seoul St. Mary’s Hospital. Cancer staging was
as described in the seventh edition of the International
Union Against Cancer TNM classification [21].Regular follow-up programs were conducted; these
involved the determination of tumor marker levels,
abdominal computed tomography (CT) and endoscopic
examination, according to our standard protocol (every
3 and 6 months for advanced and early gastric cancer,
respectively, for the first 3 years; and every 12 months
thereafter). The mean follow-up period of the enrolled
patients was 92.3 ± 68.7 months (range, 0.3 to 267.4
months; n = 1,425). Survival rates were repeatedly deter-
mined using the registration data of the Korea National
Statistical Office (KNSO) and medical records.
Written informed consent was obtained from the
patient for publication of this report and any accompany-
ing images. This study was approved by the institutional
review board of the ethical committee of the College of
Medicine, Catholic University of Korea (KC11RISI0686).
Statistical analysis
Differences between groups were analyzed using the
t-test for continuous variables and the χ2 test or Fisher’s
exact test for proportions. Survival analysis was per-
formed using Kaplan-Meier methods with a log-rank
test for univariate analysis, and multivariate analysis for
survival was performed using a Cox proportional hazards
model with the ‘Backward LR’ method. Statistical ana-
lyses were performed with SPSS version 13.0 (SPSS,
Inc., Chicago, IL, USA), and P-values <0.05 were taken to
indicate statistical significance.Results
There were no significant differences in surgical proced-
ure, including fulfillment of curative resection, between
patients diagnosed with the three histological types
(Table 1). In terms of clinicopathological characteristics,
uMAC patients were significantly older and had tumors
of larger diameter. A diffuse type of Lauren’s classifica-
tion was most common in SRC patients and intestinal
type was not observed. Lymphatic and perineural inva-
sion were significantly lower in SRC than in the other
types and vascular invasion was higher in uMAC. In
contrast to uMAC tumors, which were present at an
advanced stage with deeper invasion and more lymph
node involvement, SRC was typically detected at an earl-
ier stage. PDAC tumors tended to be detected at stages
between those of uMAC and SRC (Table 2).
There was a significant difference in overall five-year
survival between patients with SRC (77.4%) and those
with PDAC (64.0%, P<0.001) or uMAC (48.1%, P<0.001).
The five-year survival rates also differed significantly
between patients with PDAC and uMAC (P = 0.024)
(Figure 1). Of the 1,212 patients who underwent cura-
tive resection, the overall five-year survival of patients
with SRC (84.8%) was significantly higher than that of
Table 1 Operative findings
Variable PDAC uMAC SRC P-value
n= 1002 n= 54 n= 320
Extent of resection, n (%)
Subtotal 683 (68.2) 38 (70.4) 230 (71.9) 0.448
Total 319 (31.8) 16 (29.6) 90 (28.1)
Lymph node dissection, n (%)
D1 66 (6.6) 6 (11.1) 23 (7.2) 0.167
D1+ 54 (5.4) 1 (1.9) 26 (8.1)
More than D2 882 (88.0) 47 (87.0) 271 (84.7)
Reconstruction, n (%)
Billroth-I 95 (9.5) 5 (9.3) 44 (13.8) 0.240
Billroth-II 588 (58.7) 31 (57.4) 186 (58.1)
Roux-en-Y 319 (31.8) 18 (33.3) 90 (28.1)
Combined resection, n (%)
Present 123 (12.3) 8 (14.8) 31 (9.7) 0.356
Absent 879 (87.7) 46 (85.2) 289 (90.3)
Curability, n (%)
Curative 876 (87.4) 45 (83.3) 291 (90.9) 0.132
Non-curative 126 (12.6) 9 (16.7) 29 (9.1)
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P<0.001), and there was significant difference in five-
year survival between PDAC and uMAC (P = 0.039)
(Figure 2).
In a comparison of five-year survival rates in the three
histological groups by pathological stage, there were no
significant differences among either all or curatively
resected patients (Table 3). In addition, no significant
difference in the five-year survival rates was detected
among any pathological T/N-stage (data not shown).
Multivariate analysis using a Cox proportional hazard
regression model showed that older age, male gender,
depth of invasion, lymph node metastasis and curability
were independently associated with a poor prognosis
(Table 4). Among patients who had undergone curative
resection, older age, tumor diameter, depth of invasion
and lymph node metastasis were identified as independ-
ent prognostic factors (Table 5). Histological type was
not an independent prognostic factor in either group.
Of the 1,212 patients who underwent curative resec-
tion, 290 (23.9%) experienced a recurrence. There was a
significant difference among the three groups (P<0.001),
with uMAC and SRC patients having the highest and
lowest recurrence rates, respectively. However, there was
no significant difference in recurrence rates among the
groups according to pathological stage (stage I, P =
0.626; stage II, P = 530; stage III, P = 0.574). In addition,
there were no significant differences in the pattern of re-
currence (P = 0.819) (Table 6).Discussion
Undifferentiated types of gastric adenocarcinoma are
correlated with aggressive neoplasms associated with
more extensive and infiltrative growth, lymph node me-
tastasis and distant metastasis characterized by peritoneal
dissemination and, therefore, have a worse prognosis
than differentiated types [22,23]. Prognosis for three
gastric adenocarcinomas, such as SRC, PDAC and
uMAC, which belong to the undifferentiated type, is still
not established and there were few studies to deal with
only undifferentiated-type gastric adenocarcinomas. For
the design of this study, MAC was sub-classified into
differentiated-type MAC and uMAC. By our results,
SRC and uMAC had the best and worst prognosis, re-
spectively, in a univariate analysis of overall survival.
The same trend in survival differences was observed in
curatively resected patients. Such a result for uMAC
agreed with the previous reports stating that MAC had a
dismal prognosis [16-20].
In contrast to MAC, which has shown consistent
results, data regarding the prognosis of SRC are con-
flicting, although most studies did not take into account
the differentiation category. Only one report by Fang
et al. [5] compared SRC and MAC, both of which are
mucin-producing gastric cancers. They reported that
patients with SRC had better five-year survival than
those with MAC in stages I and II gastric cancer, but
there was no difference in five-year survival in advanced-
stage cancer. However, histological type was not an
Table 2 Clinicopathological characteristics
Variable PDAC uMAC SRC P-value
n= 1002 n= 54 n= 320
Age, years (mean ± SD) 54.6 ± 12.8 57.3 ± 12.1 52.4 ± 12.0 0.003
Gender, n (%)
Male 605 (60.4) 35 (64.8) 187 (58.4) 0.637
Female 397 (39.6) 19 (35.2) 133 (41.6)
Multiplicity, n (%)
Single 982 (98.0) 53 (98.1) 316 (98.8) 0.612
Multiple 20 (2.0) 1 (1.9) 4 (1.3)
Tumor location, n (%)
Upper 108 (10.8) 4 (7.4) 22 (6.9) 0.184
Middle 392 (39.1) 17 (31.5) 141 (44.1)
Lower 452 (45.1) 31 (57.4) 139 (43.4)
Whole 50 (5.0) 2 (3.7 %) 18 (5.6)
Tumor size, cm (mean ± SD) 5.7 ± 3.7 7.1 ± 3.8 4.8 ± 3.2 <0.001
Lauren, n (%)
Intestinal type 0 (0) 0 (0) 0 (0) <0.001
Diffuse type 782 (78.0) 37 (68.5) 290 (90.6)
Mixed type 220 (22.0) 17 (31.5) 30 (9.4)
Lymphatic invasion, n (%)
Present 607 (60.6) 42 (77.8) 120 (37.5) <0.001
Absent 395 (39.4) 12 (22.2) 200 (62.5)
Vascular invasion, n (%)
Present 105 (10.5) 12 (22.2) 27 (8.4) 0.009
Absent 897 (89.5) 42 (77.8) 293 (91.6)
Perineural invasion, n (%)
Present 490 (48.9) 29 (53.7) 108 (33.8) <0.001
Absent 512 (51.1) 25 (46.3) 212 (66.3)
Depth of invasion, n (%)
T1 248 (24.8) 3 (5.6) 164 (51.3) <0.001
T2 152 (15.2) 4 (7.4) 32 (10.0)
T3 242 (24.2) 13 (24.1) 40 (12.5)
T4 360 (35.9) 34 (63.0) 84 (26.3)
Lymph node metastasis, n (%)
N0 422 (42.1) 9 (16.7) 201 (62.8) <0.001
N1 134 (13.4) 11 (20.4) 25 (7.8)
N2 131 (13.1) 10 (18.5) 27 (8.4)
N3 315 (31.4) 24 (44.4) 67 (20.9)
Pathological stage, n (%)
I 323 (32.2) 4 (7.4) 180 (56.3) <0.001
II 212 (21.2) 11 (20.4) 50 (15.6)
III 354 (35.3) 30 (55.6) 64 (20.2)
IV 113 (11.3) 9 (16.7) 26 (8.1)
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Figure 1 Survival curves of patients with mucinous adenocarcinoma (MAC), signet ring cell carcinoma (SRC), or poorly differentiated
adenocarcinoma (PDAC).
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lysis. In the present study, while there was a significantly
better five-year survival rate of SRC in all enrolled
patients, patients with SRC did not have a more favorable
five-year survival than those with uMAC and PDAC
according to pathological stage, and histological type was
also not associated with prognosis. Thus, the higher pro-
portion of early stage SRC led to its better prognosis.
The uMAC also did not have a significantly worse five-
year survival rate than the other two types in comparisonFigure 2 Survival curves for patients with MAC, SRC, or PDAC who unwith each pathological stage. Similarly, an advanced stage
of uMAC at diagnosis can explain that cause. Therefore,
follow-up and postoperative strategy, such as adjuvant
chemotherapy for undifferentiated-type gastric adenocar-
cinoma, would be tailored based on each pathological
stage, irrespective of histological type.
It is uncertain why SRC and MAC present an early
and advanced stage at diagnosis, respectively. One pos-
sible explanation regarding SRC is that SRC tends to ex-
pand superficially to mucosal and submucosal layers.derwent curative resection.
Table 3 Comparison of five-year survival rates according
to pathological stage
Stage PDAC uMAC SRC P-value
All, n (%)
I 95.3 100.0 96.6 0.575
II 77.0 81.8 84.0 0.333
III 45.9 43.3 49.2 0.791
IV 5.5 11.1 3.8 0.421
Curative, n (%)
I 95.3 100.0 96.6 0.575
II 77.6 81.8 84.0 0.369
III 48.3 44.8 53.4 0.696
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such as epigastric soreness, and can be detected at an
early stage [24]. With regard to MAC, the role of extra-
cellular mucin has been reported. Extracellular mucin of
MAC acts as an infiltrating medium and promotes the
dispersion and invasion of tumor cells to deeper layers
[10,25]. In addition, mucin can inhibit the inflammatory
and immunologic reactions of tumor cells [26].
Although it is known that undifferentiated-type gastric
adenocarcinoma is associated with the diffuse type of
Lauren classification, few studies have reported a correl-




















uMAC/SRC −0.018 0.The WHO defined the diffuse type as a histological form
comprised of poorly cohesive cells with little or no gland
formation [1], and this shape almost matched up with
the SRC type. The present study, in which the proportion
of the diffuse type was highest in SRC (90.6%), followed
by PDAC (78.0%) and uMAC (68.5%), reflected such an
association. The intestinal type of undifferentiated-type
gastric adenocarcinoma was very rare, and there was no
case of the intestinal type in the present study. The struc-
ture of the intestinal type was partially observed at the
advancing margin of undifferentiated-type gastric adeno-
carcinoma belonging to the mixed type.
In the present study, a Cox proportional hazard re-
gression model identified older age, male gender, depth
of invasion, lymph node metastasis and curability as in-
dependent prognostic factors in undifferentiated gastric
adenocarcinomas. The N1 stage did not have prognostic
significance, and the hazard ratio of the N2 stage was
low. The current study was based on the seventh edition
of the International Union Against Cancer TNM classifi-
cation, which has a narrow division of N1 and N2 stages:
N1 for one to two positive lymph nodes and pN2 for
three to six. Our previous study [27] reported the low
power of discrimination of the seventh edition N classifi-
cation owing to this narrow range. The current N stage
results in undifferentiated type cancers were also con-
sidered to be attributable to the seventh edition N
classification.l in all enrolled patients
E Hazard ratio (95% CI) P-value
093 1.727 (1.440 to 2.072) <0.001
088 1.257 (1.057 to 1.495) 0.010
111 1.164 (0.936 to 1.447) 0.171
204 1.856 (1.245 to 2.766) 0.002
188 2.353 (1.626 to 3.403) <0.001
184 4.629 (3.227 to 6.641) <0.001
175 1.080 (0.766 to 1.523) 0.661
158 1.847 (1.356 to 2.516) <0.001
136 3.005 (2.301 to 3.925) <0.001
110 3.016 (2.433 to 3.740) <0.001
114 1.074 (0.858 to 1.343) 0.534
205 0.982 (0.658 to 1.467) 0.930
Table 5 Multivariate analysis of prognostic factors for survival in enrolled patients who underwent curative resection
Variable Coefficient SE Hazard ratio (95% CI) P-value
Age, years
≥65/<65 0.667 0.108 1.949 (1.576 to 2.409) <0.001
Gender
Male/Female 0.200 0.103 1.221 (0.998 to 1.494) 0.053
Tumor size, cm
≥5/<5 0.237 0.118 1.268 (1.007 to 1.597) 0.043
Depth of invasion
T2/T1 0.582 0.208 1.789 (1.190 to 2.689) 0.005
T3/T1 0.749 0.196 2.114 (1.439 to 3.106) <0.001
T4/T1 1.433 0.196 4.192 (2.855 to 6.155) <0.001
Lymph node metastasis
N1/N0 0.015 0.192 1.016 (0.696 to 1.481) 0.936
N2/N0 0.558 0.168 1.747 (1.256 to 2.428) 0.001
N3/N0 1.161 0.143 3.195 (2.414 to 4.228) <0.001
Histology
PDAC/SRC 0.157 0.136 1.170 (0.896 to 1.528) 0.248
uMAC/SRC 0.135 0.242 1.144 (0.712 to 1.840) 0.578
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adjuvant chemotherapy were not clarified. Most patients
diagnosed as having advanced stage received adjuvant
chemotherapy, most commonly 5-FU or cisplatin-based
systemic chemotherapy, based on our institute’s guide-
lines. However, this study lacked consistency regarding
patient and drug selection because of the nature of very
long-term data, especially for second-line chemotherapy.
Conclusions
Compared with patients with PDAC, the overall survival
of patients with uMAC was significantly worse and those
with SRC had a better prognosis. However, since there
were no differences in five-year survival between histo-
logical type according to cancer stage and having no histo-
logical type was not an independent prognostic factor,
treatment strategy would be focused on the stage of
undifferentiated-type gastric adenocarcinoma at diagnosis.Table 6 Recurrence rates and patterns
Variable PDAC uMAC SRC P-value
n= 876 n= 45 n= 291
Recurrence, n (%) 228 (26.0) 20 (44.4) 42 (14.4) <0.001
Pattern, n (%)
Peritoneal 100 (43.9) 7 (35.0) 15 (35.7) 0.819
Lymphatic 34 (14.9) 3 (15.0) 9 (21.4)
Remnant stomach 15 (6.6) 2 (10.0) 1 (2.4)
Hematogenous 37 (16.2) 4 (20.0) 9 (21.4)
Combined 42 (18.4) 4 (20.0) 8 (19.0)Abbreviations
WHO: World health organization; MAC: Mucinous adenocarcinoma;
SRC: Signet ring cell carcinoma; PDCA: Poorly differentiated adenocarcinoma;
JGCA: Japanese gastric cancer association; uMAC: Undifferentiated-type
mucinous adenocarcinoma; CT: Computed tomography; KNSO: Korea
national statistical office.
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